Antenatal Receipt of Sulfadoxine-Pyrimethamine Does Not Exacerbate Pregnancy-Associated Malaria Despite the Expansion of Drug-Resistant Plasmodium falciparum: Clinical Outcomes From the QuEERPAM Study by Taylor, Steve M. et al.
M A J O R A R T I C L E
Antenatal Receipt of Sulfadoxine-
Pyrimethamine Does Not Exacerbate
Pregnancy-Associated Malaria Despite the
Expansion of Drug-Resistant Plasmodium
falciparum: Clinical Outcomes From the
QuEERPAM Study
Steve M. Taylor,1,2 Alejandro L. Antonia,1 Ebbie Chaluluka,3 Victor Mwapasa,3,4 Gaoqian Feng,5,a
Malcolm E. Molyneux,3,6 Feiko O. ter Kuile,7,8 Steven R. Meshnick,1 and Stephen J. Rogerson5
1Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, 2Division of Infectious Diseases and
International Health, Duke University Medical Center, Durham, North Carolina; 3Malawi–Liverpool–Wellcome Trust Clinical Research Programme,
4Department of Community Health, College of Medicine, Blantyre, Malawi; 5Department of Medicine (RMH/WH), University of Melbourne, Australia;
6School of Tropical Medicine, University of Liverpool, 7Child and Reproductive Health Group, Liverpool School of Tropical Medicine, United Kingdom;
and 8Department of Infectious Diseases, Tropical Medicine, and AIDS, Academic Medical Center, University of Amsterdam, The Netherlands
Background. Antenatal intermittent preventive therapy with 2 doses of sulfadoxine-pyrimethamine (IPTp-
SP) is the mainstay of efforts in sub-Saharan Africa to prevent pregnancy-associated malaria (PAM). Recent
studies report that drug resistance may cause IPTp-SP to exacerbate PAM morbidity, raising fears that current
policies will cause harm as resistance spreads.
Methods. We conducted a serial, cross-sectional analysis of the relationships between IPTp-SP receipt, SP-
resistant Plasmodium falciparum, and PAM morbidity in delivering women during a period of 9 years at a single
site in Malawi. PAM morbidity was assessed by parasite densities, placental histology, and birth outcomes.
Results. The prevalence of parasites with highly SP-resistant haplotypes increased from 17% to 100%
(P < .001), and the proportion of women receiving full IPTp (≥2 doses) increased from 25% to 82% (P < .001).
Women who received full IPTp with SP had lower peripheral (P = .018) and placental (P < .001) parasite densities
than women who received suboptimal IPTp (<2 doses). This effect was not significantly modified by the presence
of highly SP-resistant haplotypes. After adjustment for covariates, the receipt of SP in the presence of SP-resistant
P. falciparum did not exacerbate any parasitologic, histologic, or clinical measures of PAM morbidity.
Conclusions. In this longitudinal study of malaria at delivery, the receipt of SP as IPTp did not potentiate
PAM morbidity despite the increasing prevalence and fixation of SP-resistant P. falciparum haplotypes. Even
when there is substantial resistance, SP may be used in modified IPTp regimens as a component of comprehensive
antenatal care.
Pregnancy-associated malaria (PAM) is an important,
preventable cause of poor birth outcomes in malaria-
endemic areas in sub-Saharan Africa [1]. Intermittent
preventive therapy with antimalarials during preg-
nancy (IPTp) is a critical tool for reducing the inci-
dence of PAM-attributable adverse birth outcomes [2].
Sulfadoxine-pyrimethamine (SP) is the most com-
monly administered drug for IPTp owing to its long
half-life, favorable side-effect profile, and safety during
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pregnancy. However, Plasmodium falciparum strains harbor-
ing mutations associated with SP resistance are increasingly
prevalent throughout sub-Saharan Africa.
The outcome of antimalarial therapy results from complex
interactions between parasite pathogenicity, host immunity, drug
characteristics, and parasite susceptibility to drug therapy. Recent
in vitro studies have suggested that the removal of susceptible
parasites from heterogeneous parasitemias by antimalarial
therapy may facilitate the relative overgrowth of the remaining
resistant parasites and therefore potentiate their pathogenicity [3].
A recent study in Tanzania documented increases in placental
inflammation that were associated with SP receipt, suggesting
that SP may potentiate placental pathology when applied to par-
tially susceptible infections [4]. However, the effect of these pla-
cental findings upon birth outcomes was unclear. Given the
prevalence of SP resistance and the current lack of appropriate,
safe alternatives for use as IPTp, it is critical to explore the
associations between IPTp-SP, SP resistance, and delivery
outcomes in further contexts to inform malaria control policies.
Malawi adopted a policy of IPTp with SP in 1993, and despite
the subsequent development of widespread SP resistance [5],
a sustained decline in the prevalence of PAM was observed from
1997 to 2005 [6]. In view of the evidence from Tanzania [4],
we hypothesized that the emergence of SP-resistant parasites
would modify the effect of IPTp-SP and thereby potentiate pla-
cental inflammation and parasite densities and worsen birth
outcomes. The Queen Elizabeth Central Hospital Epidemiology
of Resistance in Pregnancy-Associated Malaria (QuEERPAM)
study [7] was a serial cross-sectional analysis in which we
explored the relationships between IPTp-SP, the presence of
resistant parasites at delivery, and multiple measures of adverse
delivery outcome, including parasite densities, placental
histology, maternal hemoglobin concentration, and birth weight.
METHODS
Ethics Statement
Ethical approval for this study was granted by the review
boards of the Malawi Health Sciences Research Committee,
the University of Malawi College of Medicine, and the Univer-
sity of North Carolina at Chapel Hill.
Enrollment and Sample Collection
Patient enrollment and sample collection have been described
elsewhere [6, 8]. In brief, pregnant women delivering between
July 1997 and August 2006 at Queen Elizabeth Central Hospi-
tal in Blantyre, Malawi, were invited to participate. Those who
consented to participate were queried regarding demographic
and clinical information. The receipt of SP antenatally was
obtained from antenatal clinic cards; from 1999 onward, the
date of the last dose of SP was available.
Peripheral and placental blood was used to prepare thick
blood smears, which were read by 2 microscopists for the
presence and density of P. falciparum parasites. From 1998
onward, full-thickness placental biopsies were wax embedded,
stained with modified Giemsa and/or hematoxylin and eosin,
and assessed by 2 trained observers masked to other clinical
data. Histologic indices included (1) density of parasitemia,
expressed as percentage of all observed erythrocytes that were
parasitized; (2) mononuclear cell infiltrate, expressed as per-
centage of all cells observed in the intervillous space; and (3)
semiquantitative assessment of malaria pigment deposition in
fibrin, as an indicator of chronic placental inflammation [9].
Maternal hemoglobin concentration was measured using
HemoCue, and newborns were weighed within 1 day of birth.
Genotyping Procedures
A subset of 25% of available samples from women with posi-
tive peripheral blood thick smears for P. falciparum parasites
was manually selected at random by personnel blinded to all
clinical information. From these specimens, genomic DNA
was extracted and P. falciparum parasites were genotyped for
mutations in the dihydrofolate reductase (dhfr) and dihydrop-
teroate synthase (dhps) genes by direct sequencing [7]. To
reduce contamination risk, separate work areas were main-
tained for molecular steps and filtered pipette tips were used
for all procedures.
Definitions and Statistical Analyses
Mutations were investigated at codons 51, 59, 108, and 164 of
dhfr and codons 437, 540, 581, and 613 of dhps. Haplotypes
were assigned based upon codons 51, 59, and 108 in dhfr and
437 and 540 in dhps [10]. The “quintuple mutant” haplotype
consisted of mixed or mutant alleles at all 5 loci in dhfr and
dhps; “partial wild-type” haplotypes were those with a wild-
type allele at any locus. Recent antenatal SP receipt was
defined as within 60 days prior to delivery, owing to the pro-
longed half-life and activity of SP [11]. Maternal anemia was
defined as a hemoglobin concentration <11 g/dL (any) and
<9 g/dL (moderate), and low birth weight was defined as
<2500 g. Antenatal SP use was categorized as “full IPTp” (≥2
doses) or “suboptimal IPTp” (<2 doses).
Antenatal indices and birth outcomes (parasite densities,
placental histologic indices, maternal hemoglobin concentra-
tion, and birth weight) were compared between women who
received suboptimal or full IPTp using the Kruskal-Wallis
rank test, the Student t test, or the χ2 test. The prevalence of
moderate anemia and low birth weight were compared
between groups using the χ2 test. To assess for effect modifi-
cation of the effect of IPTp upon birth outcomes, we stratified
women into those harboring partial wild-type parasites and
those with quintuple mutant parasites; after stratification, we
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repeated comparisons of birth outcomes between IPTp
groups.
To account for covariates (including the effect of the year of
delivery and the effect of resistant P. falciparum) in the analysis
of the association between IPTp-SP and birth outcomes, we
first used linear or logistic regression to compare maternal per-
ipheral parasite density, placental parasite density, maternal
hemoglobin concentration, birth weight, and the dichotomized
proportions of moderate anemia and low birth weight between
women who received suboptimal and full IPTp. Parasite den-
sities were natural log-transformed prior to regression model-
ing. Subsequently, adjusted comparisons were then computed
by repeating regression models after the inclusion of covariates
representing delivery year and P. falciparum haplotype, as well
as reported mediators of placental pathology: human immuno-
deficiency virus (HIV) infection [12], gravidity (primigravid
versus multigravid) [4], and the recent receipt of SP.
Clinical data were initially entered into Epi Info or Micro-
soft Access; all statistical analyses were ultimately performed
using Stata/IC, version 10.
RESULTS
Antenatal Indices
Full genotyping and antenatal data were available for 177 women
with P. falciparum parasites on peripheral blood smear from
1997 to 2005. The patients in this subset were similar to the
overall cohort from which they were drawn [6]. The mean
(standard deviation [SD]) age was 21.7 years (4.8) and 52% were
primigravidae (Table 1). Of 128 women tested for HIV, 45
(35.2%) were positive; 90.4% received SP antenatally, with a
mean (SD) number of doses of 1.59 (0.9). Of 120 women who
received SP for whom the date of receipt was recorded,
74 (61.7%) had received SP within 60 days prior to delivery.
Between years there were significant differences in the mean
number of SP doses (P < .001), the proportion of women receiv-
ing SP (P < .001) (Figure 1A), and the proportion of women who
received SP within the preceding 60 days (P = .002) (data not
shown).
Antenatal Associations With IPTp-SP and Drug Resistance
Overall, 67.9% of women harbored the quintuple mutant hap-
lotype, the prevalence increasing from 16.7% in 1997 to 100%
in 2005 (Figure 1B) [7]. Pure wild-type dhfr-dhps haplotypes
declined from 33.3% to 0. Overall, differences in the preva-
lences of haplotypes were significant between years (P < .001).
Using Poisson regression, the prevalence rate of the quintuple
mutant haplotype increased by an average of 11% each year
(1.11; 95% confidence interval, 1.08–1.16).
The mutation in codon 164 of dhfr was not detected in any
year; for dhps, the mutation at codon 581 was detected in 1
sample in 2004, and the mutation in codon 613 was detected
in 1 sample in 1998. No novel mutations were detected in the
sequenced segments of dhfr and dhps.
Age and HIV infection were not associated with IPTp use
(Table 1). Compared with women in the suboptimal IPTp
group, women in the full IPTp group had a higher proportion
of primigravidae (62.2% versus 41.4%; P = .006), greater mean
number of doses of SP (0.8 versus 2.3; P < .001), and a higher
proportion of women who had received SP within 60 days
prior to delivery (82.2% versus 29.8%; P < .001).
Delivery Outcomes
Of the 177 women with full antenatal and genotyping data,
missing data resulted in measurements of maternal hemo-
globin, birth weight, peripheral parasite density, placental
parasite density, and placental histology being available for
Table 1. Antenatal Indices by IPTp-SP Use and Plasmodium falciparum dhfr-dhps Haplotype









Mutant (n = 78) P Value a
Age, years, mean (SD) 21.7 (4.8) 21.2 (3.73) 22.1 (4.8) 19.9 (3.1) 21.9 (5.4) .730
HIV positive,b % 35.2 25 52.2 28.6 25.5 .062
Primigravid, % 52.0 46.4 39.0 50.0 64.1 .006
SP doses, mean (SD) 1.59 (0.9) 0.64 (0.49) 0.88 (0.33) 2.33 (0.49) 2.35 (0.66) <.001
% recent SP c 61.7 25.0 30.8 85.7 81.8 <.001
Year of enrollment, median 2001 1999 2000 2001 2004 <.001
Haplotypes assigned per Kublin et al [10].
Abbreviations: HIV, human immunodeficiency virus; IPTp, intermittent preventive therapy with antimalarials during pregnancy; SD, standard deviation;
SP, sulfadoxine-pyrimethamine.
a For comparison of suboptimal and full IPTp groups. Determined by Student t test, Kruskal-Wallis test, or χ2 test for continuous and categorical data.
b Data available only for 128 women.
c Last dose of SP received within 60 days prior to delivery. Data available only in years after 1999 for 120 women.
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176, 152, 172, 108, and 133 women, respectively. Mean (SD)
birth weight was 2834 g (417), and 13.8% of births were low
birth weight (Table 2). Mean (SD) maternal hemoglobin con-
centration was 10.6 g/dL (1.8): 58% had any anemia and
15.9% were moderately anemic. Median (interquartile range
[IQR]) parasite density in the maternal peripheral blood of
parasitemic women was 526 parasites/μL (IQR, 60–3495) and
in the placental blood was 1069 parasites/μL (IQR, 73–9185).
On placental histologic analyses, median parasite density was
8.0% (IQR, 1.5%–22.1%), median mononuclear cell infiltrate
was 4.8% (IQR, 1.8%–10.4%) of all cells in the intervillous
space, and 18.7% of women had no malaria pigment
deposition.
Parasite densities varied significantly between years: median
maternal peripheral density decreased from 1997 to 2005 from
38 748 to 97 parasites/μL and median placental parasite
density decreased from 10 470 (in 1998) to 68 parasites/μL
(both P < .001; data not shown). Additionally, placental his-
tology scores varied significantly between years: the proportion
of placentae with no malaria deposition in fibrin increased
from 7.4% to 63.6% (P < .001) and median placental parasite-
mia decreased from 23.5% to 8.1% (P < .001). Median mono-
nuclear cell infiltrate in the intervillous space varied
significantly between 2.2% and 7.9% (P = .039), but there was
no overall trend. There were no differences between years in
mean birth weight, maternal hemoglobin, or the prevalence of
any anemia or low birth weight births.
Relationship Between IPTp-SP and Delivery Outcomes
Compared with women who received suboptimal IPTp (n =
87), women who received full IPTp (n = 90) had lower
median parasite densities in the peripheral blood (226
versus 780 parasites/μL; P = .018) and placenta (168 versus
4898 parasites/μL; P < .001; Figure 2A and 2B). There were
no significant differences between women who received full
and suboptimal IPTp in median placental parasitemia by
histology (8.1% versus 8.0%; P = .995), placental inflam-
mation (median mononuclear cell infiltrate, 4.4% versus
5.8%; P = .831), mean maternal hemoglobin level (10.6
versus 10.7 g/dL; P = .757), the prevalence of moderate
anemia (13.5% versus 18.4%; P = .373), mean birth weight
(2892 versus 2776 g; P = .086), or the prevalence of low
birth weight (11.8% versus 15.8%; P = .481; Figure 2C–F).
To analyze whether the presence of resistant parasites modi-
fied the effect of IPTp, we repeated these analyses after strati-
fying by the presence of quintuple mutant parasites (Figure 2).
Although women who received full IPTp had lower peripheral
parasite densities in both the presence and the absence of
quintuple mutant parasites, the differences within each para-
site subgroup were not significant (Figure 2A). In contrast, the
receipt of full IPTp was significantly associated with lower pla-
cental parasite densities in both the presence (168 versus
2620; P = .013) and the absence (374 versus 11 575; P = .046)
of quintuple mutant haplotypes (Figure 2B). Thus, the
Figure 1. Trends in sulfadoxine-pyrimethamine (SP) use and Plasmo-
dium falciparum dhfr-dhps haplotypes over time. (A) Proportion of
women receiving SP (gray bars) and the average number of doses re-
ceived (black line); (B ) the prevalence of dhfr-dhps haplotypes over time.
Haplotypes assigned per Kublin et al [10].
Table 2. Bivariate and Multivariate Associations Between Receipt of IPTp-SP and Pregnancy Outcomes





Maternal parasite density, parasites/μL median (IQR) 526 (60–3495) 780 (105–8370) 226 (49–2118) .014 .349
Placental parasite density, parasites/μL median (IQR) 1069 (73–9185) 4898 (300–13 800) 168 (52–1072) <.001 .659
P values determined by linear regression. Parasite densities were natural log-transformed prior to inclusion in regression models.
Abbreviations: IPTp, intermittent preventive therapy with antimalarials during pregnancy; IQR, interquartile range; SP, sulfadoxine-pyrimethamine.
a Adjusted for gravidity, human immunodeficiency virus infection, delivery year, and Plasmodium falciparum dhfr-dhps haplotype.
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Figure 2. Parasitologic, histologic, and clinical delivery outcomes by intermittent preventive therapy with antimalarials during pregnancy (IPTp)–-
sulfadoxine-pyrimethamine use and stratified by Plasmodium falciparum dhfr-dhps haplotype. Gray boxes: suboptimal IPTp; white boxes: full IPTp.
(A) Median (interquartile range [IQR]) maternal peripheral parasite densities; (B ) median (IQR) maternal placental parasite densities; (C ) median (IQR)
percentage of placental parasitemia by histology; (D ) median (IQR) percentage of mononuclear cells in the intervillous space; (E ) mean (standard
deviation) maternal hemoglobin (g/dL); (F ) birth weight (g). Outcomes were compared between IPTp groups using the Student t test or the Kruskal-
Wallis test. Δ indicates difference in median or mean of the full IPTp group relative to the suboptimal IPTp group.
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presence of quintuple mutant parasites did not modify the
association of full IPTp receipt with reduced parasite densities
at delivery.
Multivariate Analyses of IPTp-SP and Delivery Outcomes
Between 1998 and 2005, there were significant decreases in
parasite densities in women who received either suboptimal or
full IPTp (Figure 3A and 3B; Supplementary Table), while
histologic indices of inflammation and parasitemia and clini-
cal outcomes of maternal hemoglobin and birth weight were
unchanged (Figure 3B–D and 3F).
After adjusting for year of delivery, HIV infection, gravidity,
and the presence of P. falciparum quintuple mutants, the
receipt of full IPTp was not associated with parasite densities,
placental histology, maternal hemoglobin concentration, or
birth weight (Table 2). In these models, only the year of
Figure 3. Pregnancy outcomes over time stratified by receipt of intermittent preventive therapy with antimalarials during pregnancy (IPTp)–sulfadoxine-pyri-
methamine. Gray boxes: suboptimal IPTp; white boxes: full IPTp. (A) Median (interquartile range [IQR]) maternal peripheral parasite density; (B ) median (IQR)
placental parasite density; (C ) median (IQR) percentage of parasitemia by histology; (D ) median (IQR) percentage of mononuclear cells in the intervillous space;
(E ) mean (standard deviation [SD]) maternal hemoglobin; (F ) mean (SD) birth weight. Neither birth weight nor placental outcomes were available for 1997.
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delivery was significantly associated with the birth outcomes.
Thus, the difference in parasite densities between women who
received suboptimal and full IPTp with SP was largely ac-
counted for by differences in the year of delivery.
DISCUSSION
In this serial, cross-sectional observational study in which SP-
resistant P. falciparum isolates emerged and fixed in parasite
populations, the receipt of IPTp with SP was not associated
with poor birth outcomes or with the exacerbation of placental
pathology. Indeed, the receipt of ≥2 doses of antenatal SP was
associated with lower parasite densities, although these differ-
ences were most closely associated with the overall sustained
declines in morbidity over the 9 years of the study. These data,
which indicate that IPTp with SP does not potentiate malaria
infection or its impact during pregnancy in Malawi, suggest
that the continuation or intensification of IPTp-SP programs
will not exacerbate PAM morbidity.
Prior studies of the clinical consequences of SP-resistant
parasites have been conflicting: a cross-sectional study in Tan-
zania suggested that late-term receipt of SP was associated with
both higher parasite densities and a greater prevalence of resist-
ant parasites [4]. However, in a randomized trial in Mozambi-
que, the receipt of SP as IPTp was not associated with PAM
morbidity [12]. Compared with these studies, our investigation
benefits by capturing a greater spectrum of P. falciparum SP
resistance and transmission. Some malarious areas are experien-
cing sustained declines in malaria transmission [13–15], and
our data are the first to describe the association of drug resist-
ance and PAM morbidity in this dynamic context: from 1997
to 2005, the prevalence of parasitemia at delivery at our study
site declined from 23.5% to 5%. Our data suggest that despite
the possibility that IPTp-SP may contribute to the selection of
quintuple mutant resistant parasites, the use of IPTp-SP is not
associated with higher parasite densities, greater placental
inflammation, or worsened delivery outcomes.
Recent reports from African settings document a decline
in IPTp-SP efficacy, highlighting the need for new PAM-
preventive strategies [6, 16, 17]. Because we focused on a
selected population of parasite-positive women (who largely
failed preventive therapy), we could not fully assess drug effi-
cacy. Nevertheless, we did not detect measurable benefit of full
IPTp. This finding may be accounted for by the increasing
uptake of insecticide-treated bed nets [6, 18] or increasing
parasite drug resistance in the setting of relative underdosing
of SP, because only 14% (24 of 177) of women received >2
doses of SP. Feasible options for the replacement of current
IPTp-SP regimens include intermittent therapy with another
drug [19], intermittent screening and treatment of antenatal
parasitemia [20], or more frequent dosing of SP [21, 22]. More
frequent SP dosing is attractive for several reasons: (1) SP’s
desirable antenatal safety profile, tolerability, and pharmacoki-
netics; (2) evidence of improved SP efficacy with more fre-
quent dosing [21–24]; (3) the limited tolerability of proposed
replacement drugs [19]; and (4) measurable success (though
suboptimal) incorporating SP administration into existing
antenatal care services throughout Africa [25], which may
facilitate the adoption of a new policy. Though IPTp-SP will
undoubtedly be eclipsed by other PAM preventive strategies, it
is likely to remain an important antenatal intervention in
many African contexts for some time, and our data from a
setting where SP resistance spread early and quickly allay fears
that SP may exacerbate PAM morbidity as resistance spreads.
Why was IPTp-SP administration in the presence of resistant
parasites not associated with greater degrees of PAM morbidity
as predicted by murine [3] and clinical [4] studies? Epidemiolo-
gically, the time period of our study covered an overall decline
in parasite prevalence among pregnant women, potentially re-
ducing the ability to detect differences. Pharmacologically, in
the setting of partial host immunity, SP is capable of clearing
infections comprising resistant parasites [26] and thus may
have limited parasite growth and placental inflammation
despite mutant parasites. Genetically, a key difference between
our study and that in Tanzania [4] is the absence of the
dhps581 mutation. Similar to a study in Mozambique [12], this
mutation is not prevalent in Malawi, whereas its promotion in
pregnant women was posited as a key consequence of SP
exposure in Tanzania. Prior in vitro allelic exchange exper-
iments [27] and clinical studies in children [28] suggest that
dhps581 does not confer substantially greater resistance or viru-
lence, whereas the quintuple mutant haplotype that we use as a
proxy for SP resistance is consistently associated with clinical
SP failure [10, 29]. Nevertheless, it should be noted that known
drug resistance genotypes might not be the only determinant of
parasite phenotype in placental malaria. Also, because drug
resistance haplotypes in sub-Saharan Africa have regional
origins [30], a mutation such as dhps581 may be linked to
mediators of pathogenicity that are heretofore undescribed and
that modify response to antimalarials.
This study is subject to several limitations. Comparison to
some prior studies [4, 12, 31] is limited owing to our analysis
of peripheral instead of placental parasitemias. Nevertheless,
the prevalence of drug-resistant genotypes between compart-
ments is tightly correlated [31, 32]. The number of women
harboring parasites with partial wild-type haplotypes was very
low in some years. Because of this, we chose to study a broad
range of clinical, parasitologic, and histologic outcomes to
maximize our ability to detect differential morbidity. Bed-net
use was not analyzed because it is not postulated to mediate
the effect of drug resistance and may not confer added
benefit when IPTp-SP coverage is high, as in our study [21].
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This successful provision of SP to most (>85%) women in our
study precluded an analysis of outcomes in women who did
not receive SP. However, accumulating evidence supports a
dose-response relationship between SP receipt and clinical
outcomes [21], suggesting that the comparison between sub-
optimal and full IPTp-SP is biologically and clinically relevant.
Finally, despite our multivariate modeling, as an observational
study that is subject to prevailing and dynamic clinical factors,
we cannot rule out confounding of the relationships between
IPTp-SP, parasite haplotype, and morbidity by unmeasured
clinical or parasite variables.
In this longitudinal observational study that benefits from
consistent patient enrollment designed to limit bias and the
rigorous assessment of a broad range of clinical, parasitologic,
and histologic delivery outcomes, the receipt of IPTp-SP and
infection with SP-resistant parasites at delivery were not
associated with the exacerbation of PAM morbidity. Our study
provides reassurance that the spread of parasites harboring the
“quintuple mutant” haplotype may not exacerbate PAM
morbidity in the context of SP use as IPTp and demonstrates
the value of longitudinal, integrated clinical and molecular
surveillance to inform policies to prevent pregnancy-associated
malaria and improve maternal and neonatal health.
Supplementary Data
Supplementary materials are available at Clinical Infectious Diseases online
(http://www.oxfordjournals.org/our_journals/cid/). Supplementary materials
consist of data provided by the author that are published to benefit the
reader. The posted materials are not copyedited. The contents of all sup-
plementary data are the sole responsibility of the authors. Questions or
messages regarding errors should be addressed to the author.
Notes
Acknowledgments. We thank Mike Mistarz for his work in the labora-
tory (University of North Carolina), Alfredo Mayor (Universitat de
Barcelona), Michel Cot (Institut de Recherche pour le Développement,
Paris), and Brian Greenwood (London School of Hygiene and Tropical
Medicine) for their comments on an earlier version of this manuscript.
We are indebted to the patients for their participation.
Financial support. This work was supported by the Malaria in Preg-
nancy Consortium, which is funded through a grant from the Bill &
Melinda Gates Foundation to the Liverpool School of Tropical Medicine (to
F. O. tK.). Sample collection was funded by a Career Development Fellow-
ship and a Senior Overseas Biomedical Research Fellowship awarded by the
Wellcome Trust (to S. J. R.) and by grants from the National Institutes of
Health (NIH; AI 49084), NIH-Fogarty International Center (5 D43
TW00908), and the Center for AIDS Research at the University of North
Carolina (to S. R. M.). The funders had no role in study design, data collec-
tion and analysis, decision to publish, or preparation of the manuscript.
Potential conflicts of interest. All authors: No reported conflicts.
All authors have submitted the ICMJE Form for Disclosure of Potential
Conflicts of Interest. Conflicts that the editors consider relevant to the
content of the manuscript have been disclosed in the Acknowledgements
section.
References
1. Steketee RW, Nahlen BL, Parise ME, Menendez C. The burden of
malaria in pregnancy in malaria-endemic areas. Am J Trop Med Hyg
2001; 64:28–35.
2. ter Kuile FO, van Eijk AM, Filler SJ. Effect of sulfadoxine-pyrimetha-
mine resistance on the efficacy of intermittent preventive therapy for
malaria control during pregnancy: a systematic review. JAMA 2007;
297:2603–16.
3. Wargo AR, Huijben S, de Roode JC, Shepherd J, Read AF. Competi-
tive release and facilitation of drug-resistant parasites after therapeutic
chemotherapy in a rodent malaria model. Proc Natl Acad Sci U S A
2007; 104:19914–9.
4. Harrington WE, Mutabingwa TK, Muehlenbachs A, et al. Competitive
facilitation of drug-resistant Plasmodium falciparum malaria parasites
in pregnant women who receive preventive treatment. Proc Natl Acad
Sci U S A 2009; 106:9027–32.
5. Sridaran S, McClintock SK, Syphard LM, Herman KM, Barnwell JW,
Udhayakumar V. Anti-folate drug resistance in Africa: meta-analysis
of reported dihydrofolate reductase (dhfr) and dihydropteroate
synthase (dhps) mutant genotype frequencies in African Plasmodium
falciparum parasite populations. Malar J 2010; 9:247.
6. Feng G, Simpson JA, Chaluluka E, Molyneux ME, Rogerson SJ. De-
creasing burden of malaria in pregnancy in Malawian women and its
relationship to use of intermittent preventive therapy or bed nets.
PLoS One 2010; 5:e12012.
7. Taylor SM, Antonia A, Feng G, et al. Adaptive evolution and fixation
of drug-resistant Plasmodium falciparum genotypes in pregnancy-
associated malaria: 9-year results from the QuEERPAM study. Infect
Genet Evol 2012; 12:282–90.
8. Rogerson SJ, Chaluluka E, Kanjala M, Mkundika P, Mhango C,
Molyneux ME. Intermittent sulfadoxine-pyrimethamine in pregnancy:
effectiveness against malaria morbidity in Blantyre, Malawi, in 1997-
99. Trans R Soc Trop Med Hyg 2000; 94:549–53.
9. Rogerson SJ, Pollina E, Getachew A, Tadesse E, Lema VM, Molyneux
ME. Placental monocyte infiltrates in response to Plasmodium falci-
parum malaria infection and their association with adverse pregnancy
outcomes. Am J Trop Med Hyg 2003; 68:115–9.
10. Kublin JG, Dzinjalamala FK, Kamwendo DD, et al. Molecular
markers for failure of sulfadoxine-pyrimethamine and chlorproguanil-
dapsone treatment of Plasmodium falciparum malaria. J Infect Dis
2002; 185:380–8.
11. White NJ. Intermittent presumptive treatment for malaria. PLoS Med
2005; 2:e3.
12. Menendez C, Serra-Casas E, Scahill MD, et al. HIV and placental in-
fection modulate the appearance of drug-resistant Plasmodium falci-
parum in pregnant women who receive intermittent preventive
treatment. Clin Infect Dis 2011; 52:41–8.
13. O’Meara WP, Bejon P, Mwangi TW, et al. Effect of a fall in malaria
transmission on morbidity and mortality in Kilifi, Kenya. Lancet
2008; 372:1555–62.
14. Bhattarai A, Ali AS, Kachur SP, et al. Impact of artemisinin-based
combination therapy and insecticide-treated nets on malaria burden
in Zanzibar. PLoS Med 2007; 4:e309.
15. Ceesay SJ, Casals-Pascual C, Erskine J, et al. Changes in malaria
indices between 1999 and 2007 in The Gambia: a retrospective analy-
sis. Lancet 2008; 372:1545–54.
16. Harrington WE, Mutabingwa TK, Kabyemela E, Fried M, Duffy PE.
Intermittent treatment to prevent pregnancy malaria does not confer
benefit in an area of widespread drug resistance. Clin Infect Dis 2011;
53:224–30.
17. Luntamo M, Kulmala T, Mbewe B, Cheung YB, Maleta K, Ashorn P.
Effect of repeated treatment of pregnant women with sulfadoxine-
pyrimethamine and azithromycin on preterm delivery in Malawi: a
randomized controlled trial. Am J Trop Med Hyg 2010; 83:1212–20.
Resistance in Pregnancy Malaria • CID 2012:55 (1 July) • 49
18. Menendez C, Bardaji A, Sigauque B, et al. A randomized placebo-
controlled trial of intermittent preventive treatment in pregnant
women in the context of insecticide treated nets delivered through
the antenatal clinic. PLoS One 2008; 3:e1934.
19. Briand V, Bottero J, Noel H, et al. Intermittent treatment for the pre-
vention of malaria during pregnancy in Benin: a randomized, open-
label equivalence trial comparing sulfadoxine-pyrimethamine with
mefloquine. J Infect Dis 2009; 200:991–1001.
20. Tagbor H, Bruce J, Agbo M, Greenwood B, Chandramohan D.
Intermittent screening and treatment versus intermittent preventive
treatment of malaria in pregnancy: a randomised controlled non-
inferiority trial. PLoS One 2010; 5:e14425.
21. Maiga OM, Kayentao K, Traore BT, et al. Superiority of 3 over 2 doses
of intermittent preventive treatment with sulfadoxine-pyrimethamine
for the prevention of malaria during pregnancy in Mali: a randomized
controlled trial. Clin Infect Dis 2011; 53:215–23.
22. Filler SJ, Kazembe P, Thigpen M, et al. Randomized trial of 2-dose
versus monthly sulfadoxine-pyrimethamine intermittent preventive
treatment for malaria in HIV-positive and HIV-negative pregnant
women in Malawi. J Infect Dis 2006; 194:286–93.
23. Kapito-Tembo A, Meshnick SR, van Hensbroek MB, Phiri K, Fitzgerald
MMwapasa V. Marked reduction in prevalence of malaria parasitemia
and anemia in HIV-infected pregnant women taking cotrimoxazole
with or without sulfadoxine-pyrimethamine intermittent preventive
therapy during pregnancy in Malawi. J Infect Dis 2011; 203:464–72.
24. Gill CJ, Macleod WB, Mwanakasale V, et al. Inferiority of single-dose
sulfadoxine-pyrimethamine intermittent preventive therapy for malaria
during pregnancy among HIV-positive Zambian women. J Infect Dis
2007; 196:1577–84.
25. van Eijk AM, Hill J, Alegana VA, et al. Coverage of malaria protection
in pregnant women in sub-Saharan Africa: a synthesis and analysis of
national survey data. Lancet Infect Dis 2011; 11:190–207.
26. Cravo P, Culleton R, Hunt P, Walliker D, Mackinnon MJ. Antimalar-
ial drugs clear resistant parasites from partially immune hosts. Anti-
microb Agents Chemother 2001; 45:2897–901.
27. Triglia T, Wang P, Sims PF, Hyde JE, Cowman AF. Allelic exchange at
the endogenous genomic locus in Plasmodium falciparum proves the
role of dihydropteroate synthase in sulfadoxine-resistant malaria.
EMBO J 1998; 17:3807–15.
28. Gesase S, Gosling RD, Hashim R, et al. High resistance of Plasmodium
falciparum to sulphadoxine/pyrimethamine in northern Tanzania and
the emergence of dhps resistance mutation at Codon 581. PLoS One
2009; 4:e4569.
29. Picot S, Olliaro P, de Monbrison F, Bienvenu AL, Price RN, Ringwald
P. A systematic review and meta-analysis of evidence for correlation
between molecular markers of parasite resistance and treatment
outcome in falciparum malaria. Malar J 2009; 8:89.
30. Pearce RJ, Pota H, Evehe MS, et al. Multiple origins and regional dis-
persal of resistant dhps in African Plasmodium falciparum malaria.
PLoS Med 2009; 6:e1000055.
31. Mockenhaupt FP, Bedu-Addo G, Eggelte TA, et al. Rapid increase in
the prevalence of sulfadoxine-pyrimethamine resistance among Plas-
modium falciparum isolated from pregnant women in Ghana. J Infect
Dis 2008; 198:1545–9.
32. Mockenhaupt FP, Bedu-Addo G, Junge C, Hommerich L, Eggelte TA,
Bienzle U. Markers of sulfadoxine-pyrimethamine-resistant Plasmo-
dium falciparum in placenta and circulation of pregnant women.
Antimicrob Agents Chemother 2007; 51:332–4.
50 • CID 2012:55 (1 July) • Taylor et al
